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Wen Chen1,2, Yinghua Xia1,2, Yan Hong3, Brian J Hall2,4,5 and Li Ling1,2*Abstract
Background: To examine the predictors of continued drug- and sex-related HIV-risk behaviors among drug users in
methadone maintenance therapy (MMT) programs in China.
Methods: We followed a sample of 5,035 drug users enrolled for the first time in MMT programs at baseline,
6 months, and 12 months utilizing a longitudinal prospective study design. Drug users’ HIV-risk behaviors, MMT
characteristics, and drug use, were assessed at all three waves using a structured interview and HIV/HCV status was
assessed at baseline and 12-month follow-up using biological specimens.
Results: The point prevalence of HIV was 7.6% and 78.4% for HCV at baseline. Results of generalized linear mixed
logistic regression models revealed that HIV-positive MMT clients were more likely to engage in drug injection
(aOR = 1.70) and syringe sharing (aOR = 4.73). HCV-positive clients were more likely to inject drugs (aOR = 2.58),
share syringes (aOR = 1.97), and have multiple sexual partners (aOR = 1.47). Adherence to MMT was the most
significant predictor of reduced HIV-risk behaviors.
Conclusions: Our data confirmed the positive effects of MMT on HIV prevention and underscored the urgency
for programs to reduce HIV risk in HIV- and HCV-positive clients. There is a pressing need to strengthen existing
counseling services for HIV-positive drug users to reduce their drug-related risk behaviors and to provide counseling
for HCV-positive drug users. Further studies are needed to explore interventions to address high dropout rates and
low adherence among MMT clients.
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Globally, around 36 million people are addicted to heroin
and opium, and many of them are HIV positive or at high
risk of becoming infected and transmitting the virus to
others [1]. Methadone maintenance therapy (MMT) is
one of the most popular opioid replacement therapies
designed to treat opioid dependence with more than
one million people in MMT worldwide [2]. Despite the
controversy surrounding MMT [3,4], existing literature has
documented the effectiveness of MMT in reducing the
risks of drug overdose, drug injection, and transmission* Correspondence: lingli@mail.sysu.edu.cn
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reproduction in any medium, provided the orof HIV and other blood- borne diseases [5-11]. Most of
these studies were conducted in Western countries;
limited data exist from developing countries like China,
where more than 1.5 million drug users were recently
introduced to MMT [12].
Illicit drug use reemerged in China in the early 1980s,
when China adapted an open-door policy towards the
West [13]. The rates of drug users continued to climb
during the next decade and expanded rapidly from
70,000 in 1990 to 1.5 million in 2011 [12,13]. The Chinese
government employed the same “eradication” policies
instituted in the 1950s in response to the growing drug-
abuse epidemic. Drug use was portrayed in the media as
one of the four “social evils” subject to “fierce crack-down.”
Periodic “strike-hard” campaigns were organized that
targeted individuals engaging in drug use. Identified drugtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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forced abstinence treatment or “reeducation through labor
camps” [14]. Such policies failed to reduce the number of
drug users but instead pushed them further underground.
Concurrently, the first HIV epidemic broke out among
injection drug users (IDU) in Yunnan in 1989 [13,15]. As
of 2010, 28.6% of HIV infections in China were attributed
to IDU [16].
In response to the growing HIV epidemic, the Chinese
government adopted a more pragmatic approach toward
drug abuse. In 2004, MMT was piloted in eight cities;
MMT was scaled up nationwide since 2006 [17]. By
September 2011, a total of 716 clinics across the country
were approved to provide MMT and since that time,
more than 332,996 drug users have been enrolled in
the program [16]. The MMT system in China has thus
become the largest single drug-treatment system in the
world [18].
According to the national guidelines of MMT, partici-
pation in government-sponsored MMT is voluntary, and
each client is required to pay 10 yuan (about $1.50) per
day for the treatment. At enrollment, clients receive
comprehensive medical examinations, which include
testing for HIV, HCV, TB, syphilis, and liver and kidney
diseases. Clients with TB and liver diseases are then
referred to appropriate clinics for treatment. These
examinations are performed annually during the course
of MMT. If clients test positive for HIV, they are referred
to the local CDC for antiretroviral treatment (ART). In
addition, clients are required to take monthly urine tests
for illicit drug use. Clients need to visit an MMT clinic
every day. Clinicians provide them with an appropriate
dose of methadone based on their individual needs.
Clinicians also provide HIV prevention counseling services.
A client who fails to return to a MMT clinic for 7 con-
secutive days is considered to have dropped out of MMT
[19]. A high dropout rate has been observed in most
MMT clinics in China [20-23]. The most typical reason
for dropping out is detention by police or incarceration
in detoxification centers. Other leading causes include
trying to quit opiate use without MMT, and conflicts
with job schedules [22,24].
Existing studies on MMT in China revealed that HIV-
seropositive rates among IDU who participated in MMT
were between 11% to 29% [10,25,26]. Studies indicate
that most MMT clients continue to engage in HIV-risk
behaviors while enrolled in MMT programs [10,27]. There-
fore, identifying the risk factors associated with continued
HIV risks is a public health priority. Available data on
these risk factors come primarily from cross-sectional
studies with small sample sizes [27-30]. The current study
overcomes these limitations by utilizing a longitudinal
prospective study design with a large sample of MMT
clients. The aims of this investigation were to assess thechanges in drug- and sex-related risk behaviors among
MMT clients and identify the predictors of continued
HIV risks.Methods
Study site
Our study was conducted in Guangdong Province on
the southern coast of China. Guangdong is the frontier
of China’s economic reform and forerunner in terms of
HIV/AIDS epidemic; the total number of HIV-infected
individuals was 37, 723 in 2012 October [31] and 26.6%
of HIV infections in Guangdong were transmitted through
sharing injection equipment [32]. We employed a two-
stage stratified sampling methodology by first choosing
nine cities in Guangdong Province with different levels
of economic development, and then randomly selecting
one or two MMT clinics from each participating city. A
total of 12 MMT clinics were selected as data collection
sites for the current study representing a diverse group
of 300,000 drug users [33].
Participants
Clients were eligible to participate in our study if they
met the following criteria: (a) current opioid or heroin
dependence according to the International Classification
of Diseases-10 (ICD-10) [34], (b) age 20 or older, (c)
residence in the area/city where the MMT clinic was
located (according to current Chinese policies, only
residents with local household registration are eligible
for local MMT services), (d) willingness to participate
and provide informed consent, and (e) enrollment in
the participating MMT program for the first time (to
reduce the potential contamination from other HIV-
prevention or drug treatment programs). At the time of
the study, no other HIV prevention programs were of-
fered in the 12 participating MMT clinics. A total of
5,624 new voluntary MMT clients meeting our criteria
were enrolled in our stud. Among these participants,
319 were not tested for HIV and were excluded from the
data analysis. The final sample included 5,305 participants
who were followed over one year. The first follow-up
at 6 months had a sample size of 3,123 (58.9%), and
the second follow-up at 12 months had sample size of
2,061 (38.9%).
Data collection
Data collection began in January 2006 and concluded in
October 2010. At enrollment in the study, participants
completed an informed consent and were interviewed
by an experienced clinician in a private space at the
MMT clinic using a structured interview questionnaire.
The questionnaire consisted of demographic information
and HIV-related risk behaviors designed by the National
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Maintenance Treatment for Opium Dependents in China,
and was widely used in MMT related studies in China
[35,36]. Participants completed the same survey about
their HIV- and drug-related behaviors at each follow-up
and provided blood samples for HIV and HCV testing
at baseline and 12-month follow-up as a part of the
MMT protocol. Study participation was voluntary, and no
participant received any payment or gifts for participating.
The study protocol was approved by the Institutional
Review Board [37] at the Sun Yat-sen University School
of Public Health.Measurement
Demographic characteristics
Were collected during the baseline survey, including age,
gender, education, employment status, marital status, and
history of drug abuse.Table 1 Demographic and MMT characteristics of MMT client
Characteristics Baseline
(n = 530
Age (years), mean (SD) 38.65(6.1
Sex n (%)
Male 4916 (92
Female 389(7.33
Employment status n (%)
Employed 3066(57.
Unemployed 2239(42.
Marriage status n (%)
Married 2449(46.
Unmarried 2856(53.
Education n (%)
Primary school 1038(19.
Junior school 3335(62.
Senior school or higher 932(17.5
HIV n (%)
Positive 401(7.56
Negative 4904(92.
HCV n (%)
Positive 3909(78.
Negative 1078(21.
Years of drug use before MMT mean (SD) 15.02(5.0
Methadone dosage (mg/day) –
mean (SD)
Treatment adherence (days) –
mean (SD)
Longest duration of abstinence (months) median (IQR) –MMT characteristics
The MMT clinicians recorded clients’ daily methadone
dosage and other medical information. Client attendance
was tracked and the criterion of MMT dropout (and
from this current study) was missing 7 consecutive days of
MMT. In addition, clients provided monthly urine samples
to test for illicit drug use. From these data, we identified
three treatment characteristics of the participants;
first, mean dosage of methadone, the average amount
of methadone the client had taken; second, treatment
adherence, the number of days the client adhered to
the treatment guidelines and took daily dosage of
methadone as required; and third, longest duration of
abstinence (LDA), defined as the longest duration of
negative urine tests for drug use.
HIV-risk behaviors
Drug-related risk behaviors were assessed by inquiring if
the participant had injected drugs and whether he or shes during the course of treatment
6-month follow-up 12-month follow-up
5) (n = 3123) (n = 2061)
7) 38.63(6.15) 38.85(6.24)
.67) 2865(91.74) 1898(92.09)
) 258(8.26) 163(7.91)
79) 1928(61.74) 1287(62.45)
21) 1195(38.26) 774(37.55)
16) 1445(46.26) 968(46.97)
84) 1698(53.74) 1093(53.03)
57) 611(19.56) 406(19.70)
87) 1923(61.58) 1241(60.21)
7) 589(18.86) 414(20.19)
) 206(6.60) 148(7.18)
44) 2917(93.40) 1913(92.82)
38) 2427(79.73) 1626(80.34)
62) 617(20.27) 398(19.66)
4) 15.22(5.06) 15.45(4.88)
51.11(22.05) 52.38(22.17)
183.00 267.00
(95.00 ~ 183.00) (152.00 ~ 336.00)
4.00 (2.00 ~ 6.00) 4.00(2.00 ~ 7.00)
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risk behaviors included whether the participant had
unprotected sex in the previous sexual intercourse or
whether he or she had multiple sexual partners (more
than one) in the past 3 months.HIV- and HCV-positive status
MMT clients provided blood samples for HIV and HCV
serum antibody testing at enrollment and 12-month
follow-up in the MMT program. Samples were first
screened by latex chromatographic, positive samples
were further confirmed using the immunoblotting method
by the local Centers of Disease Control. Meanwhile,
blood samples from each client were tested for hepatitis
C antibody by enzyme-linked immunosorbent assay
(ELISA). Pre- and posttest counseling services wereTable 2 Demographic and MMT characteristics between retai
Characteristic 6-mo
Retained
(n = 3123)
Age (yrs) mean (SD) 38.63(6.15)
Sex n (%)
Male 2865 (91.74)
Female 258 (8.26)
Employment n (%)
Employed 1928 (61.74)
Unemployed 1195 (38.26)
Marital status n (%)
Married 1445 (46.26)
Unmarried 1698 (53.74)
Education n (%)
Primary school 611(19.56)
Junior school 1923(61.58)
Senior school or higher 589(18.86)
HIV n (%)
Positive 206(6.60)
Negative 2917(93.40)
HCV n (%)
Positive 2427(79.73)
Negative 617(20.27)
Yrs of drug use before MMT 15.22(5.06)
mean (SD)
Methadone dosage (mg/day) mean (SD) 51.11(22.05)
Treatment adherence (days), mean (SD) 183.00
(95.00 ~ 183.00)
Longest duration of abstinence (months) median (IQR) 4.00(2.00 ~ 6.00)
*p < 0.05, **p < 0.01, ***p < 0.001.provided. National guidelines were followed in all counsel-
ing and testing services.
Data analysis
First, we used t-test or Fisher’s exact test to compare the
key demographics, MMT characteristics, and HIV- and
HCV-infection status across the samples at baseline, first
follow-up, and second follow-up as well as between
the retained sample and dropout sample. Second, we
identified the time trend of both drug- and sex-related
HIV-risk behaviors during the course of treatment. To
best utilize available data and to account for intra-class
correlation (ICC) resulting from repeated measures, we
used generalized linear mixed models (GLMM) for binary
outcomes with a logit link function. Finally, we used
logistic regression with GLMM to estimate unadjusted
and adjusted odds ratio (aOR) and 95% confidencened and dropout clients at 6- and 12- month follow-up
nth follow-up 12-month follow-up
Dropped out Retained Dropped out
(n = 2182) (n = 2061) (n = 3244)
38.23(6.10) ** 38.85(6.24) 38.27(6.07) **
2071 (94.91) *** 1898 (92.09) 3038 (93.65) **
111 (5.09) 163 (7.91) 206 (6.35)
1118 (51.24) *** 1287 (62.45) 1759(54.22) ***
1064 (48.76) 774 (37.55) 1485(45.78)
1004 (46.01) 968 (46.97) 1481(45.65) *
1178(53.99) 1093 (53.03) 1763(54.96)
427(19.57) * 406(19.70) 632(19.48) ***
1412(64.71) 1241(60.21) 2094(64.55)
343(15.72) 414(20.19) 518(15.97)
195(8.94) ** 148(7.18) 253(7.80)
1987(91.06) 1913(92.82) 2991(92.20)
1482(76.27) ** 1626(80.34) 2283(77.05) **
461(23.73) 398(19.66) 680(22.95)
14.74(5.00) ** 15.45(4.88) 14.75(5.12) ***
44.10(18.94) *** 52.38(22.17) 45.59(19.98) ***
36.00 267.00 53.00
(14.00 ~ 90.00) *** (152.00 ~ 336.00) (18.00 ~ 143.00) ***
0.00(0.00 ~ 1.00) *** 4.00(2.00 ~ 7.00) 1.00(0.00 ~ 2.75) ***
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behaviors. Four bivariate models (to produce the “un-
adjusted OR” for four types of HIV risk behaviors) and
four multivariable models (to produce the “adjusted OR”
for four types of HIV risk behaviors) were conducted
on outcomes obtained at 12-month follow-up. Variance
components, with the VC command, was chosen as co-
variance structure for the repeated measures, based on
Akaike’s information criteria (AIC) [38]. All statistical
analyses were performed using SAS 9.3 and the SAS
procedure PROC GLIMMIX (SAS Institute Inc., Cary,
NC, USA).Results
Demographic and MMT characteristics over 12 months of
follow-up
As depicted in Table 1, at the baseline, the mean age of
MMT participants was 38.6 years (SD = 6.17), and the
mean length of drug use prior to MMT was 15 years
(SD = 5). Most participants were male (93%), 46% were
married, 58% were employed, and 18% had completed
secondary school. Approximately 7.6% were HIV positive
and 78.4% were HCV positive. Participants in the first
follow-up had a mean 183 treatment-adherence days
and a median 4 months of abstinence. Participants in the
second follow-up had a mean 267 treatment-adherence
days and a median 4 months of abstinence. As shown in
Table 2, the retained participants and dropouts differed
significantly in most key demographic and MMT charac-
teristics. Dropouts were more likely to be younger, male,
less educated, HIV-positive, HCV-positive, with a shorter
drug use history, a lower dosage of methadone, and a
shorter duration of abstinence.Table 3 Changes in HIV risk behaviors during the course of M
Risk behaviors Baseline
(n = 5305)
Drug injection in the past 1 month
Yes 4368(82.34)
No 937(17.66)
Syringe sharing in the past 1 month
Yes 988(18.62)
No 4317(81.38)
Unprotected sex at last sexual encounter
Yes 1782(56.88)
No 1351(43.12)
Multiple sexual partners in the past 3 months
Yes 401(9.35)
No 3887(90.65)
Main effect of time: *p < 0.05, ***p < 0.001.Changes of HIV risk behaviors at three measurements
As shown in Table 3, drug-related HIV-risk behaviors
decreased throughout the course of treatment. Injecting
drugs in the past month decreased from 82% at baseline
to 30% at first follow-up and 22.5% at second follow-up.
Sharing needles decreased from 18.6% to 4.9% to 4.0%.
Sex-related risk behaviors had mixed responses to the
treatment. For instance, having unprotected sex in the
last sexual intercourse decreased from 56.9% to 54.1% at
first follow-up and remained at the same level at second
follow-up. Having multiple sexual partners in the past
3 months decreased from 9.4% at baseline to 6.8% at first
follow-up but increased to 9.3% at second follow-up.Predictors of continued HIV-risk behaviors
Tables 4 and 5 present the predictors of drug- and sex-
related risk behaviors. In the multivariable model, after
controlling for potential confounders and ICC, the fol-
lowing variables significantly increased the risk of drug
injection: younger age, longer history of drug use, being
male, unemployment, not completing secondary school,
being unmarried, HIV positive, HCV positive, lower mean
dosage of methadone, lower level of treatment adherence
and shorter duration of abstinence.
The following variables significantly increased the risk
of sharing needles: younger age, longer history of drug
use, being HIV or HCV positive, lower level of treatment
adherence, shorter duration of abstinence, having un-
protected sex prior to MMT and having multiple sexual
partners prior to MMT.
The significant predictors for unprotected sex included
younger age, longer history of drug use, unemployment,
being married, being HIV or HCV positive, lower meanMT treatment
6-month follow-up 12-month follow-up
(n = 3123) (n = 2061)
937(30.00) 464(22.51) ***
2186(70.00) 1597(77.49)
154(4.93) 83(4.03) ***
2969(95.07) 1978(95.97)
1078(54.09) 695(54.64) *
915(45.91) 577(45.36)
213(6.83) 118(9.30) ***
2905(93.17) 1151(90.70)
Table 4 Generalized linear mixed models (GLMM) logistic regression results: Predictors of continued drug-related
risk behaviors
Variables Drug injection Syringe sharing
Unadjusted OR Adjusted OR Unadjusted OR Adjusted OR
Age 0.99 (0.98 ~ 0.99) *** 0.98(0.97 ~ 0.99) *** 0.97(0.96 ~ 0.98) *** 0.97(0.95 ~ 0.98)***
Years of drug use before MMT 1.03(1.02 ~ 1.04) *** 1.04(1.03 ~ 1.06) *** 1.03(1.02 ~ 1.05) *** 1.03(1.01 ~ 1.05)**
Sex
Male 1.55(1.35 ~ 1.79) *** 1.35(1.08 ~ 1.69) * 1.62(1.25 ~ 2.10) *** 1.27(0.90 ~ 1.79)
Female Reference Reference Reference Reference
Employment status
Employed 0.96 (0.89 ~ 1.04) 0.85(0.74 ~ 0.97) * 1.04(0.92 ~ 1.17) 1.02(0.85 ~ 1.23)
Unemployed Reference Reference Reference Reference
Education
Senior school or higher 0.69(0.61 ~ 0.78) *** 0.71(0.58 ~ 0.88) ** 0.61(0.49 ~ 0.75) *** 0.81(0.59 ~ 1.12)
Junior school 1.00(0.91 ~ 1.11) 0.98(0.83 ~ 1.16) 1.03(0.23 ~ 4.67) *** 1.19(0.95 ~ 1.49)
Primary school Reference Reference Reference Reference
Marriage status
Married 0.75(0.69 ~ 0.81) *** 0.81(0.71 ~ 0.93) ** 0.73(0.65 ~ 0.82) *** 0.91(0.75 ~ 1.10)
Unmarried Reference Reference Reference Reference
HIV status
Positive 2.12(1.80 ~ 2.49) *** 1.70(1.23 ~ 2.35) ** 5.22(4.44 ~ 6.15) *** 4.73(3.53 ~ 6.35) ***
Negative Reference Reference Reference Reference
HCV status
Positive 1.87(1.70 ~ 2.06) *** 2.58(2.19 ~ 3.04) *** 1.67(1.40 ~ 1.99) *** 1.97(1.51 ~ 2.58) ***
Negative Reference Reference Reference Reference
MMT mean dosage 1.00a(1.00b ~ 1.00c) * 1.00d(0.99 ~ 1.00e) ** 1.00(1.00 ~ 1.00) 1.00(1.00 ~ 1.00)
Treatment adherence 0.42(0.36 ~ 0.48) *** 0.18(0.16 ~ 0.19) *** 0.34(0.30 ~ 0.38) *** 0.42(0.36 ~ 0.48) ***
Longest duration of abstinence 0.86(0.85 ~ 0.87) *** 0.91(0.89 ~ 0.93) *** 0.86(0.84 ~ 0.88) *** 0.92(0.89 ~ 0.95) ***
Unprotected sex
Yes 1.05(0.95 ~ 1.16) 1.13(0.99 ~ 1.29) 1.13(0.96 ~ 1.33) 1.27(1.06 ~ 1.53) ***
No Reference Reference Reference Reference
Multiple sexual partners
Yes 1.11(0.96 ~ 1.29) 0.91(0.75 ~ 1.12) 1.42(1.15 ~ 1.77) ** 1.49(1.17 ~ 1.90) **
No Reference Reference Reference Reference
*P < 0.05, **P < 0.01, ***P < 0.001.
Exact value: a: 0.998; b: 0.996; c: 0.999; d: 0.995; e: 0.998.
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shorter duration of abstinence and injecting drugs prior
to MMT.
The significant predictors for multiple sexual partners
included younger age, being unmarried, HIV negative,
HCV positive, lower level of treatment adherence, shorter
duration of abstinence and sharing needles prior to MMT.
Discussion
Our data revealed that MMT client HIV-risk behaviors
had decreased over the course of treatment, especially in
the first 6 months, indicating positive effects of MMT onHIV prevention. These findings were consistent with
previous studies on the effect of MMT [9,39-41], especially
in China [42,43]. We found that HIV-positive clients
were 1.70 times more likely to continue to engage in
drug injection and 4.73 times more likely to continue
to share syringes compared to their counterparts at
12 month follow-up, even after controlling for other
factors (Table 4), suggesting that awareness of HIV status
and HIV counseling may not be sufficient to reduce
drug-related risk behaviors [44-46]. In contrast to their
drug-related behaviors, HIV-positive individuals in our
study were less likely to continue to have unprotected
Table 5 Generalized linear mixed models (GLMM) logistic regression results: Predictors of continued sexual
risk behaviors
Variables Unprotected sex Multiple sexual partners
Unadjusted OR Adjusted OR Unadjusted OR Adjusted OR
Age 1.03(1.03 ~ 1.04) *** 1.02(1.01 ~ 1.03) *** 0.97(0.96 ~ 0.98) *** 0.98(0.97 ~ 1.00a) *
Years of drug use before MMT 1.02(1.01 ~ 1.03) *** 1.01(1.00b ~ 1.02) * 0.99(0.97 ~ 1.00) 0.99(0.98 ~ 1.01)
Gender
Male 1.03(0.86 ~ 1.22) 1.10(0.92 ~ 1.32) 0.80(0.60 ~ 1.08) 0.80(0.59 ~ 1.08)
Female Reference Reference Reference Reference
Employment status
Employed 0.80(0.72 ~ 0.88) *** 0.82(0.74 ~ 0.91) *** 1.09(0.93 ~ 1.27) 1.16(0.99 ~ 1.36)
Unemployed Reference Reference Reference Reference
Education
Senior school or higher 1.08(0.92 ~ 1.26) 1.11(0.94 ~ 1.31) 0.94(0.73 ~ 1.22) 0.98(0.75 ~ 1.27)
Junior school 0.99(0.87 ~ 1.12) 1.02(0.89 ~ 1.17) 1.16(0.95 ~ 1.42) 1.11(0.90 ~ 1.36)
Primary school Reference Reference Reference Reference
Marriage status
Married 1.43(1.30 ~ 1.58) *** 1.35(1.21 ~ 1.50) *** 0.57(0.49 ~ 0.67) *** 0.58(0.49 ~ 0.69) ***
Unmarried Reference Reference Reference Reference
HIV status
Positive 0.43(0.34 ~ 0.55) *** 0.43(0.33 ~ 0.55) *** 0.61(0.42 ~ 0.89) * 0.49 (0.33 ~ 0.74) **
Negative Reference Reference Reference Reference
HCV status
Positive 0.97(0.85 ~ 1.11) 0.84(0.73 ~ 0.96) *** 1.48(1.21 ~ 1.83) *** 1.47(1.18 ~ 1.84) **
Negative Reference Reference Reference Reference
MMT mean dosage 0.99(0.99 ~ 1.00c) *** 1.00d(0.99 ~ 1.00e) *** 1.00(1.00 ~ 1.00) 1.00(1.00 ~ 1.01)
Treatment adherence 1.00f(0.99 ~ 1.00g) * 0.99(0.99 ~ 1.00h) *** 0.98(0.97 ~ 0.99) *** 0.98(0.97 ~ 0.99) ***
Longest duration of abstinence 0.99(0.97 ~ 1.00i) * 0.96(0.94 ~ 0.98) *** 0.97(0.95 ~ 0.99) ** 0.97 (0.95 ~ 1.00j) *
Drug injection
Yes 1.12(0.99 ~ 1.27) 0.75(0.65 ~ 0.86)*** 0.92(0.75 ~ 1.13) 0.93(0.74 ~ 1.15)
No Reference Reference Reference Reference
Syringes sharing
Yes 0.88(0.77 ~ 1.00) 0.97(0.84 ~ 1.12) 0.77(0.63 ~ 0.93) ** 0.77(0.63 ~ 0.95) *
No Reference Reference Reference Reference
*P < 0.05, **P < 0.01, ***P < 0.001.
Exact value: a: 0.999; b: 1.001 c: 0. 996; d: 0.996; e: 0.998; f: 0.996; g: 0.999; h: 0.997; i: 0.999; j: 0.996.
Chen et al. Harm Reduction Journal 2013, 10:23 Page 7 of 10
http://www.harmreductionjournal.com/content/10/1/23sex and have multiple sexual partners (Table 5). Although
HIV-prevention counseling is a part of MMT programs
in China, our data underscore the inadequacy or lim-
ited effect of drug-related HIV-prevention counseling.
Programs to reduce drug-risk behaviors targeting HIV-
positive individuals are urgently needed [40,47,48].
HCV-positive clients were 2.58 times more likely to
continue to inject drugs, 1.97 times more likely to continue
to share syringes (Table 4), and 1.47 times more likely
to continue to have multiple sexual partners (Table 5);
their drug-related HIV-risk behaviors resembled those
in previous studies [49-51]. More than 70% of IDU inGuangdong province are infected with HCV (in our study
78% were HCV positive) [52], but HCV counseling and
treatment were not part of the MMT protocol partly
because the MMT programs were established in response
to the growing HIV/AIDS epidemic. Our data suggest
an urgent need to include effective HCV-prevention
counseling in MMT.
We note that the most significant factor in reducing
HIV risks was treatment adherence; in other words, MMT
clients who better adhered to the treatment and stayed
in the program longer were more likely to reduce their
drug- or sex-related risk behaviors, suggesting that more
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Such findings suggest the need for measures to promote
adherence among MMT clients. Inconsistent results were
reported in previous studies on the relationship between
treatment adherence and methadone dosage. Ramli M
et al. demonstrated that there was a positive association
between these two factors [53], on the contrary, methadone
maintenance dose was not associated with improved
treatment adherence in Zhao L’s study [54]. The current
study did not focus on this relationship; however, further
studies are clearly required to investigate impact of
methadone dose on treatment adherence. Other risk
factors included younger age, longer history of drug abuse,
being male, unemployment, less education, and being
single. These findings provide important information
by identifying at-risk individuals who could benefit from
targeted interventions to reduce their HIV risk.
The current study has several limitations. First, we
had a relatively high attrition rate: 38% at first follow-up
and 61% at second follow-up. We did not employ any
retention efforts during the study as it was a longitudinal
observational study rather than an intervention study.
Although the rate of dropout is high, this is typical in
MMT clinics and highlights the need for future research
to increase retention in these programs. The attrition rates
observed in the current study were similar to previous
MMT studies in China [20-23]. Nevertheless, the data
presented in the current study might be biased towards
“good clients.” We learned that those who dropped out
were more likely to be male, younger, unemployed, and
HIV positive and have shorter history of drug abuse.
Therefore, future studies are needed to target these drug
users who were more likely to drop out of MMT and
determine reasons for dropping out. Second, we have
used self-reported data for all study predictors; thus,
recall or social desirability biases might be present.
Third, we included only a limited number of outcome
and independent variables in the survey; other important
psychosocial measures, such as mental health status as
well as structural factors such as social support and social
networks [55] were not included. These variables might
explain more about the relationship between continued
HIV-risk behaviors and MMT characteristics. Finally,
our study was conducted in selected MMT clinics in
Guangdong Province of south China; the data might
not be generalizable to other MMTclients living elsewhere
in China.
Despite these limitations, our study represents one of
the first efforts to use a prospective design to evaluate
the factors associated with continued HIV-risk behaviors
during the course of MMT. We found that HIV- and
HCV-positive status were strongly associated with
drug- and sex-related risk behaviors, which underscore
the urgency to strengthen HIV counseling, especiallydrug-risk reduction in the current MMT programs.
Given the high prevalence of HCV in China we adding
counseling services for HCV- positive MMT clients is
urgently needed. The high attrition rate and strong
association of MMT adherence and HIV-risk reduction
suggest the importance of enhancing adherence among
MMT clients. MMT has been scaled-up nationwide in
China since 2006 [17], and its “revolving-door” effect has
been reported in previous studies [10,56,57]. Because the
positive effect of MMT and its extensive reach have been
confirmed in the past decade [2,5,6], now is a critical time
to adjust the program to improve implementation effect-
iveness. Motivating drug users to adhere to the program
longer and reducing HIV risks and drug abuse require
greater efforts than the MMT program. They require
structural interventions, such as programs to reduce
the stigma associated with drug users and HIV-positive
individuals as well as a social support system for vul-
nerable drug users, especially younger, unmarried, and
unemployed individuals.
Conclusions
Our data confirmed the positive effects of MMT on HIV
prevention and underscored the urgency for programs
to reduce HIV risk in HIV- and HCV-positive clients.
We call to strengthen the existing counseling services
for HIV-positive drug users to reduce their drug-related
risk behaviors and to provide counseling for HCV-positive
drug users. Future studies are needed to explore interven-
tions to address high dropout rates and low adherence
among MMTclients.
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